Custom cover image
Key Clinical Trials in Erectile Dysfunction / by Culley C. Carson
Resource type: Ressourcentyp: Buch (Online)Book (Online)Language: English Series: SpringerLink BücherPublisher: London : Springer-Verlag London Limited, 2007Description: Online-Ressource (X, 79 p, digital)ISBN:- 9781846284281
- 616.6
- 616.69220610724
- 610
- RC870-923.2 RC875-899.5
- RC889
- 2007 A-216
- ZWJ 11.1
- WJ 11.1
Contents:
Summary: Contained within this short volume are some of the Key Clinical Trials relating to the medical treatment of erectile dysfunction (ED). In an attempt to understand the potential significance, a critique of the studies' strengths and weaknesses is included as well as a diagrammatic summary of the trial design and key results. Most of the studies have appeared in peer group reviewed journals and each trial included has been done so on the basis of the influence it will have on the treatment of ED. With the recent launch and continuing developments of new drugs in this field, the management of ED has become an increasingly important aspect of urological practice. It is estimated that over 20 million men in Europe alone suffer at some time in their life from ED. This is the first book to bring together in a single volume a critical review of all the major trials in ED. It will be an essential reference for both clinicians and research workers in urology, sexual dysfunction and related disorders.PPN: PPN: 1649008449Package identifier: Produktsigel: ZDB-1-SMI | ZDB-2-SME
Contents; 1. The Earliest Carefully Controlled Clinical TrialEvaluating Oral Pharmacotherapy (Yohimbine)in ED; 1.1 Key Trial References; 1.2 Importance of Study; 1.3 Study Design; 1.4 Key Results; 1.5 Conclusions from Original Reports; 1.6 Strengths; 1.7 Weaknesses; 1.8 Relevance; 2. A Description of the Pioneering Work That Led tothe First Approved Agents for ED: Giles Brindley,the Needle, and the Penis (Phenoxybenzamine); 2.1 Key Trial References; 2.2 Importance of Study; 2.3 Study Design; 2.4 Key Results; 2.5 Conclusions from Original Reports; 2.6 Strengths; 2.7 Weaknesses; 2.8 Relevance
3. The Pivotal Study Showing That IntracorporalInjection of Vasoactive Agents (Papaverine orPhenoxybenzamine) Was EffectivePharmacotherapy3.1 Key Trial References; 3.2 Importance of Study; 3.3 Study Design; 3.4 Key Results; 3.5 Conclusions from Original Reports; 3.6 Strengths; 3.7 Weaknesses; 3.8 Relevance; 4. The First Placebo-Controlled Study on the Benefitsof Intracorporal Administration of VasorelaxantAgents to ED Patients (Papaverine/PhentolamineCombination); 4.1 Key Trial References; 4.2 Importance of Study; 4.3 Study Design; 4.4 Key Results; 4.5 Conclusions from Original Reports
4.6 Strengths4.7 Weaknesses; 4.8 Relevance; 5. Representative Study on the Use of Yohimbine in theTreatment of Organic ED; 5.1 Key Trial References; 5.2 Importance of Study; 5.3 Study Design; 5.4 Key Results; 5.5 Conclusions from Original Reports; 5.6 Strengths; 5.7 Weaknesses; 5.8 Relevance; 6. Defining the Therapeutic Ratio for IntracavernosalAdministration of Prostaglandin E 1 (Alprostadil); 6.1 Key Trial References; 6.2 Study Funding; 6.3 Importance of Study; 6.4 Study Design; 6.5 Key Results; 6.6 Conclusions from Original Reports; 6.7 Strengths; 6.8 Weaknesses; 6.9 Relevance
7. An Elegant Long-Term Trial Assessing the ClinicalProfile of Intracavernosal Prostaglandin E (Alprostadil)7.1 Key Trial References; 7.2 Importance of Study; 7.3 Study Design; 7.4 Key Results; 7.5 Conclusions from Original Reports; 7.6 Strengths; 7.7 Weaknesses; 7.8 Relevance; 8. Evaluation of Novel Combination (Vasoactive Intestinal Polypeptide and Phentolamine) as Intracavernosal Therapy; 8.1 Key Trial References; 8.2 Study Funding; 8.3 Importance of Study; 8.4 Study Design; 8.5 Key Results; 8.6 Conclusions from Original Reports; 8.7 Strengths; 8.8 Weaknesses; 8.9 Relevance
9. Now-Classic Study on the Use of IntraurethralProstaglandin E 1 (Alprostadil)9.1 Key Trial References; 9.2 Study Funding; 9.3 Importance of Study; 9.4 Study Design; 9.5 Key Results; 9.6 Conclusions from Original Reports; 9.7 Strengths; 9.8 Weaknesses; 9.9 Relevance; 10. Route of Administration Has a Considerable Impacton Clinical Profile: A Comparison of Intraurethraland Intracavernosal Alprostadil; 10.1 Key Trial References; 10.2 Importance of Study; 10.3 Study Design; 10.4 Key Results; 10.5 Conclusions from Original Reports; 10.6 Strengths; 10.7 Weaknesses; 10.8 Relevance
11. First Clinical Data on Sildenafil: The Arrival of OralPharmacotherapy
No physical items for this record